169 results about "Human heart" patented technology

Method and systems are provided for characterizing blood flow in an atrioventricular valve of the human heart, the atrioventricular valve connecting an atrium with a corresponding ventricle of the heart, the ventricle being fluidly coupled to a particular vessel that transports blood outside the ventricle blood, which involve obtaining image data of the heart and identifying contours of the atrium and a region within the particular vessel within the image data. A time-density curve for the atrium can be calculated from the contour of the atrium and densitometric image data derived from the image data. A time-density curve for the region of the particular vessel can be calculated from the contour of the vessel region and the densitometric image data. Data that characterizes at least one regurgitation fraction related to the atrioventricular valve can be calculated from such time-density curves.

The invention relates to a multi-mode heart and cerebral hemodynamics monitoring method and device, and belongs to the technical field of medical equipment. According to the method, brain absorbance information and pulse wave information at the middle artery of the brain are obtained based on a near infrared spectrum technology by utilizing the relevance among the cardiac output, blood pressure, intracranial pressure and cerebral perfusion pressure of a human body, cardiac output information and cuff-free blood pressure information are obtained based on a thoracic impedance method, and physiological signals are obtained based on the two methods; and carrying out fusion processing to obtain a multi-modal signal, and further constructing a non-invasive monitoring model of non-invasive intracranial pressure, cardiac output, blood pressure and cerebral perfusion pressure, so as to realize continuous non-invasive monitoring reflecting human heart and cerebral hemodynamic parameters. According to the invention, through fusion application of multi-mode signals, the mechanism of cardio-cerebral hemodynamics interaction can be effectively disclosed, and a more effective, safer and noninvasive monitoring means is provided for clinic.

The present invention relates to a radiofrequency electrode ablation catheter for ventricular septal therapy with a cooling function, which is used for performing radiofrequency electrode ablation and has a cooling function for preventing carbonization of body (ventricular septum) tissue around the electrode, wherein radiofrequency energy is applied to the ventricular septum during radiofrequency electrode ablation to perform ventricular septal therapy (e.g., therapy for hypertrophic cardiomyopathy, a disease in which the left ventricular septum of the heart of an animal or human body becomes thickened, therapy requiring reduction of the ventricular septum, or ventricular tachycardia, etc.). The radiofrequency catheter for ventricular septal therapy according to a preferred embodiment of the present invention includes a septal insertion portion and a body portion.

The invention discloses a respiratory training quantitative evaluation method, which comprises the following steps of: acquiring physiological parameter characteristics related to heart rate, respiration and brain function of a human body through a human body physiological data acquisition platform, and performing dimensionality reduction, dimensionless processing and weighted summation on the characteristics to obtain a respiratory training quantitative evaluation result. The method comprises the following specific steps: firstly, collecting human heart rate, respiration and brain function related physiological features through a physiological parameter collection platform, then calculating feature classification weight of each dimension through random forest and cross validation and removing redundant feature dimensions, and then removing dimensions of features in a feature subset through a dimensionless method; and finally, performing weighted summation on the feature data through the feature weight to obtain a respiratory training quantitative evaluation result. Quantitative evaluation is carried out on respiratory training, so that people can be helped to formulate more scientific respiratory training strategies and methods.

The invention discloses a non-contact electrocardio detection method which comprises the following steps: transmitting a frequency modulation continuous wave signal to the heart part of a human body by using an MIMO millimeter wave radar so as to obtain an echo signal reflected by the human body and pre-process the echo signal to obtain a discrete three-dimensional radar signal; enhancing the discrete three-dimensional radar signal by using a 2D beam forming technology to obtain a 2D signal; extracting a target area signal from the 2D signal, and performing phase extraction on the extracted target area signal to obtain phase data; the method comprises the following steps: constructing a WaveGRU-Net network comprising an MODWT module, a CNN module and a Bi-GRU module; and training the WaveGRU-Net network by using the phase data so as to output a reconstructed electrocardiogram by using the trained WaveGRU-Net network, thereby realizing non-contact electrocardiogram detection. According to the method, accurate extraction of the electrocardiosignal is realized, and meanwhile, the signal reconstruction precision is improved.

A system and a computer-implemented method are provided for generating at least one 4-dimensional medical image segmentation for at least one structure of a human heart. The method includes providing a first 4-dimensional medical image comprising the at least one structure of the human heart, the medical image being based on a computed tomography scan image; generating a segmentation of at least part of the provided first 4-dimensional medical image using at least one first trained artificial neural network, wherein the at least one first trained artificial neural network is configured as a convolutional processing network with U-net architecture; and generating at least one 4-dimensional medical image segmentation for the at least one structure of the human heart based at least on the segmentation generated by the at least one first trained artificial neural network.

The invention belongs to the technical field of biological medicine, and particularly discloses an artificial valve tissue calcification model and a preparation method and application thereof. The preparation method comprises the following steps: providing human valvular interstitial cells; the method comprises the following steps: providing a hydrogel system, wherein the hydrogel system comprises type I collagen, fibrinogen and Matrigel matrigel; constructing an engineered heart valve tissue strip by taking the hydrogel system as a skeleton structure between valve interstitial cells; and culturing the engineered heart valve tissue strip by using a calcification induction culture solution, so that the valve tissue generates a calcification phenotype. The model provided by the invention can generate a valve calcification phenotype which is similar to that after human heart valve calcification and is represented by valve interstitial cell activation, extracellular matrix remodeling such as collagen mass secretion and calcium deposition region generation. The model provided by the invention is low in cost, can be produced in batches, meets the research on the pathogenesis of extracorporeal valve calcification, and makes up for the dilemma that no artificial valve calcification model is available for drug research and development at present.

Implant for improving coaptation of an atrioventricular valve in a human heart, the atrioventricular valve having a first and a second native leaflet, an anterolateral and posteromedial commissure between the first and the second native leaflet, and an annulus adjacent a wall of an atrium of the heart. The implant including a frame that includes a middle frame section that frames and supports an artificial central leaflet. The artificial central leaflet is configured to cover a middle region of the first native leaflet. The middle frame section includes a bend formed between a first region of the artificial central leaflet and a second region of the artificial central leaflet that forms a coaptation plane for coaptation with the second native leaflet. The frame further including two side frame sections extending at opposite sides of the middle frame section and configured to contact side regions of the first native leaflet.

An embodiment of the invention provides a system for automatically deriving a parameter of a human heart from ultrasound results. A first neural network is arranged to receive a plurality of echocardiographic images and to classify the images into one of at least a two-chamber view and a four-chamber view. A second neural network is arranged to receive echocardiographic images comprising a two- or four-chamber view and to identify the endocardial border of the left ventricle (LV) for each view. End-systole and end-diastole images are then identified and a parameter such as LV volume, ejection fraction, global longitudinal strain and regional longitudinal strain is calculated.

Provided herein are maturation media and methods for maturing early embryonic human cardiac organoids to mature human cardiac organoids. The maturation medium comprises a cell growth medium comprising a medium supplement comprising: one or more fatty acids, a triiodothyronine (T3) growth hormone, insulin, one or more antioxidants, a sugar, and carnitine; one or more additional fatty acids; additional carnitine or creatine; and a further T3 growth hormone. The maturation medium may also include one or more additional sugars, additional antioxidants, and growth factors. The methods include contacting an early embryonic human cardiac organoid with one or more maturation media to produce a mature human cardiac organoid.

The present disclosure provides use of a long non-coding RNA (lncRNA) in preparation of a drug for controlling myocardial infarction, and belongs to the technical field of biomedicine. The present disclosure further provides use of a recombinant vector with a nucleic acid sequence of lncRNA CIR6 or a recombinant virus strain with the nucleic acid sequence of lncRNA CIR6 in inducing MSC differentiation into a cardiomyocytes in vitro, wherein the MSC is selected from the group consisting of a bone marrow-derived mesenchymal stem cell (BMSC) and an umbilical cord-derived mesenchymal stem cell (UCMSC). In the present disclosure, the lncRNA-CIR6 is derived from human heart. In vivo and in vitro experiments have shown that lncRNA-CIR6 induces the differentiation of the MSC into the cardiomyocyte; meanwhile, the cardiomyocyte detected by flow cytometry has an average transformation rate of not less than 90%.

Implant for improving coaptation of an atrioventricular valve in a human heart, the atrioventricular valve having a first and a second native leaflet, an anterolateral and posteromedial commissure between the first and the second native leaflet, and an annulus adjacent a wall of an atrium of the heart. The implant including a frame that includes a middle frame section that frames and supports an artificial central leaflet. The artificial central leaflet is configured to cover a middle region of the first native leaflet. The middle frame section includes a bend formed between a first region of the artificial central leaflet and a second region of the artificial central leaflet that forms a coaptation plane for coaptation with the second native leaflet. The frame further including two side frame sections extending at opposite sides of the middle frame section and configured to contact side regions of the first native leaflet.

The invention relates to the technical field of medical instruments, and provides a valve prosthesis and a preparation method thereof.The valve prosthesis comprises a valve frame and a flexible leakage-proof part arranged on the valve frame; the direction, where blood can flow, of the valve prosthesis is defined as the vertical direction, the valve frame comprises a positioning part which can be positioned on the upper side of a human heart valve ring, and the flexible leakage-proof piece comprises a containing part which can be filled with blood and is located on the lower side of the positioning part after being filled with the blood. The containing part comprises an inward extending section extending inwards in the radial direction of the valve frame and an edge part located on the edge of the inward extending section, at least part of the edge part extends outwards in the radial direction of the valve frame to form an outward extending section, and the outward extending section is located on the upper side of the inward extending section. According to the technical scheme, the problem of perivalvular leakage is solved.

The present invention provides an artificial heart pump device and a preparation method of a magnetic diaphragm pump, belonging to the field of medical devices. The artificial heart pump device includes a magnetic diaphragm pump system and a magnetic field generating system; the magnetic diaphragm pump includes a magnetic diaphragm and a non-magnetic pump body; after the magnetic diaphragm is magnetized radially, it deforms under a uniform magnetic field; the non-magnetic pump body cooperates with the magnetic diaphragm to generate elastic deformation, and realizes the function of pumping blood by changing the volume of the magnetic diaphragm pump; a hose connects each artery or vein where the magnetic diaphragm pump is connected to the human heart to complete the transportation and circulation of blood in the human blood vessels and the magnetic diaphragm pump; a one-way valve controls the one-way flow of blood; the magnetic field generating system generates a uniform magnetic field along the axial direction of the magnetic diaphragm. The artificial heart pump device provided by the present invention has higher operation reliability and longer service life.

1. The name of the design product: arm type electronic sphygmomanometer. 2. The use of the design product: the design product is mainly used for detecting human heart rate pulse and blood pressure. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

This document provides a method for generating human heart organoids (hHO) with integrated macrophages (MPs), the method comprising adding monocytes to a first culture medium containing hHOs, wherein the hHOs have been differentiated for at least 5 days, and agitating the hHOs, monocytes, and the first culture medium or fresh culture medium to generate hHOs with integrated MPs. hHOs with integrated MPs prepared by the disclosed method are also provided.

The invention relates to a simulator comprising a flexible simulation chamber simulating a living body chamber, the flexible simulation chamber having at least one opening; a valve comprising a valve leaflet; a papillary muscle entity model; and chordae tendineae connecting the papillary muscle entity model and the valve leaflets; at least one valve arm extends through the flexible simulation cavity, so that the far end of the valve arm is arranged in the flexible simulation cavity, the near end of the valve arm is arranged outside the flexible simulation cavity, the far end of the valve arm is fixed relative to the papillary muscle entity model, and the position of the far end of the valve arm can be controlled from the near end; and a control device for controlling the simulation process. Such a simulator allows for precise simulation of motion of a living body chamber, such as the left ventricle or the right ventricle of a human heart, in which case precise rotation and / or other motion of the chamber during a pulsation can be simulated.

The present application relates to a kind of D type personality prediction method and system based on millimeter wave radar, method includes: when target patient is diagnosed with coronary heart disease, the human heart rate variability HRV data of target patient is collected using millimeter wave radar, short-term frequency domain analysis is carried out to HRV data, and the frequency domain index parameter of target patient is obtained;Whether target patient is D type personality according to preset D type personality prediction algorithm and frequency domain index parameter is predicted;If target patient is D type personality, then target patient is carried out according to D type personality coronary heart disease prognosis.The non-contact HRV data acquisition of coronary heart disease patient is realized using millimeter wave radar, and after short-term frequency domain analysis is carried out to HRV data, the frequency domain index parameter for D type personality prediction is obtained, so as to realize the prediction of D type personality.Compared with the existing scale, the accuracy is higher, and the disease prognosis of D type personality coronary heart disease patient can be effectively improved.

A shunt device is configured to be implanted at a site of an elongated shunt opening in a tissue wall between a left atrial appendage (LAA) and a great cardiac vein (GCV) of a human heart. The shunt device includes a body portion through which a flow path extends, one or more anchoring portions connected to the body portion, and an elongated flow path opening configured to align with the elongated shunt opening in the tissue wall to permit blood to flow from the LAA into the GCV through the shunt device along the flow path.

The invention provides a composition, cell culture and application of the composition in differentiation of human pluripotent stem cells to myocardial cells and / or construction of human-derived heart organoid, and belongs to the technical field of cell engineering. The invention provides a composition. The composition comprises a fatty acid receptor antagonist, a fatty acid synthetase inhibitor and a fatty acid oxidation activator. The composition provided by the invention can regulate cell metabolism, breaks through the contradiction that the proliferation capacity and the cell maturity cannot be obtained at the same time in the traditional technology, can maintain the myocardial cells in a proliferation stage, and obtains the myocardial cells with relatively mature structures and functions, and the contractility of 3D heart organs constructed by the myocardial cells is greatly improved. The invention provides a high-quality cell source for myocardial regeneration treatment, high-throughput drug cardiotoxicity screening and heart disease mechanism research, and has remarkable clinical application value and industrialization prospect.

A selective blocking door device includes a coupling assembly that is configured to be removably secured to a mating base that is secured to a human heart. A frame assembly is secured to the coupling assembly, and a closure assembly is configured to linearly displace within opposing lateral slots of the frame assembly from a first open position to a second closed position. In the open position, no portion of the closure assembly is configured to be aligned with a central aperture of the mating base such that the central aperture is clear of any obstruction by the closure assembly. In the closed position, a portion of the closure assembly is configured to be aligned with the central aperture of the mating base such that the central aperture is covered and obstructed by a portion of the closure assembly.

1. The name of the product of this design: Arm Cuff Sphygmomanometer (ZK‑B888). 2. Purpose of the product of this design: used to detect human heart rate, pulse and blood pressure. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: Stereoscopic diagram 1.

The invention discloses a non-invasive measurement method for measuring the stress of a heart stent, and belongs to the technical field of stress measurement. Firstly, an experimental data set is collected, a digital human body model and a power equipment digital model are generated, and a virtual scene is established; test points are set in the digital human body model, and contribution indexes of the test points are calculated and marked in combination with the experimental data set; secondly, setting an equivalent point for each marked test point in a free space in the virtual scene, and calculating a weight index and setting a weight according to the position of each equivalent point; and finally, measuring the electric field intensity and the magnetic flux density of the equivalent point, and calculating the electric field intensity and the magnetic flux density of the corresponding marked test point in combination with the weight. And calculating the electromagnetic wave energy density of the human heart stent, and measuring the stress distribution of the heart stent according to a virtual displacement method. Through in-vitro free space equivalent point measurement and a weight optimization mechanism, high-precision non-invasive measurement of the heart stent stress in a complex electromagnetic environment is realized.

Docking devices can be configured to be positioned at a native valve of a human heart to provide structural support for docking a prosthetic valve. The docking devices generally have coiled structures that define an inner space in which the prosthetic valve can be held. Some docking devices can be adjusted from a first wider configuration which facilitates easier advancement of the docking device around the valve anatomy, to a second narrower configuration after the docking device has been delivered to more securely hold the prosthetic valve. The docking device may also be better held in position at the native valve after adjustment to the narrower configuration. Some docking devices include a stabilization segment or double coil configuration, where a main coil region is configured to securely hold a prosthetic valve, while a stabilization coil region is configured to more stably hold the docking device at the native valve.

The invention discloses a portable human heart imaging hardware system based on bioelectrical impedance. The system comprises an excitation signal processing module, a detection signal conditioning module and a digital processing module. The excitation signal processing module adopts a DAC (Digital-to-Analog Converter) to generate an excitation signal, and after voltage amplification and band-pass filtering, the excitation signal drives an excitation electrode through an analog switch; the detection signal conditioning module switches a measuring electrode through an analog switch, a programmable instrumentation amplifier is combined with an RDAC digital potentiometer to realize self-adaptive gain adjustment of a detection signal, flexible gain of the signal is realized, and the signal is sent to an ADC after being filtered; the digital processing module carries out digital demodulation on the collected signals, extracts amplitude and phase information and then transmits the amplitude and phase information to an upper computer for image reconstruction. The flexible signal gain mechanism of the system realizes a full-custom signal gain curve, breaks through the fixed magnification gain limitation of the traditional integrated PGA, adapts to the impedance change of different individuals and experimental media, and improves the signal-to-noise ratio of the system, thereby obtaining more accurate cardiac impedance acquisition data.

1. The name of this design product: digital stethoscope. 2. Purpose of this product design: This product design is used for auscultating human heart and lung sounds. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

A total artificial heart system includes at least one artificial ventricle coupled to (or capable of being coupled to) a chamber or a vessel of a human heart, and at least one drive system coupled to the artificial ventricle, the drive system including at least one implanted electric motor. The drive system causes the artificial ventricle to contract and expand.

An implantable system detecting electrical signals of a human or animal heart includes a processor, a memory unit, a first detection unit for atrial activity, a second detection unit for right ventricular activity and a third detection unit for left ventricular activity. The system automatically performs steps at regular intervals including detecting an intrinsic right atrial activity using the first detection unit; detecting an intrinsic right ventricular activity using the second detection unit; determining a time between the intrinsic right atrial activity and the intrinsic right ventricular activity, and storing this time as atrioventricular conduction time. Additionally or alternatively the steps include detecting an intrinsic right ventricular activity using the second detection unit; detecting an intrinsic left ventricular activity using the third detection unit; and determining a time between the intrinsic right ventricular activity and the intrinsic left ventricular activity, and storing this time as interventricular conduction time.

The invention belongs to the technical field of medicines, and particularly relates to a milk acylation modified Myh6 protein and application thereof. The antigen polypeptide for identifying the heart failure marker has an amino acid sequence as shown in SEQ ID NO: 1, lysine located at the 9th site is subjected to milk acylation modification, and the heart failure marker is milk acylation modified Myh6 protein; the milk acylation modified Myh6 protein is a lysine milk acylation modified protein (Myh6-K1897) which is located at the 1897 site of a wild type Myh6 protein. The Myh6-K1897 can be used as a marker for identifying heart failure as a target spot, is a set of novel and perfect protein milk acylation molecular regulation and control system, can judge the interaction between Myh6 and Tin, and is used for treating the core and key of heart failure. The research provides a new and powerful treatment strategy for the treatment of human heart failure diseases.